[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,038
  • Shares Outstanding, K 28,946
  • Annual Sales, $ 26,550 K
  • Annual Income, $ -91,720 K
  • EBIT $ -60 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.48
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.74
  • Most Recent Earnings $-0.88 on 11/14/25
  • Next Earnings Date 09/04/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 96.61%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 5) 0.0340 (4.19%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.7780 to 0.8460

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6670 +6.88%
on 06/09/26
1.0750 -33.68%
on 06/04/26
-0.0636 (-8.19%)
since 05/12/26
3-Month
0.6670 +6.88%
on 06/09/26
1.4500 -50.83%
on 04/08/26
-0.5571 (-43.87%)
since 03/12/26
52-Week
0.6670 +6.88%
on 06/09/26
4.3500 -83.61%
on 07/22/25
-1.0471 (-59.49%)
since 06/12/25

Most Recent Stories

More News
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
Celularity Appoints Rick Gonzalez as Chief Commercial Officer

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company, today announced...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
NEXGEL Appoints Ian Blackman as Chief Financial Officer

Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL”...

CELU : 0.7129 (-1.91%)
NXGL : 0.5510 (-6.61%)
NXGLW : 0.0271 (-9.97%)
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified...

CELU : 0.7129 (-1.91%)
NXGL : 0.5510 (-6.61%)
NXGLW : 0.0271 (-9.97%)
Celularity Announces Closing of Transaction with NexGel

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April...

CELU : 0.7129 (-1.91%)
CELUW : 0.0057 (unch)
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  ...

CELU : 0.7129 (-1.91%)
NXGL : 0.5510 (-6.61%)
NXGLW : 0.0271 (-9.97%)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 0.8526
2nd Resistance Point 0.8195
1st Resistance Point 0.7662
Last Price 0.7129
1st Support Level 0.6798
2nd Support Level 0.6467
3rd Support Level 0.5934

See More

52-Week High 4.3500
Fibonacci 61.8% 2.9431
Fibonacci 50% 2.5085
Fibonacci 38.2% 2.0739
Last Price 0.7129
52-Week Low 0.6670

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.